1. Аронов Д.М. Применение коэнзима Q10 в кардиологической практике. РМЖ. 2004; 12 (15): 905–9.
2. Ключников С.О., Гнетнева Е.С., Накостенко Т.Н., Сухоруков В.С. Применение Кудесана (Коэнзима Q10) у часто болеющих детей. Педиатрия. 2007; 2: 80–3.
3. Коровина Н.А., Рууге Э.К. Использование коэнзима Q10 в профилактике и лечении. Применение антиоксидантного препарата кудесан (коэнзим Q10 с витамином Е) в кардиологии. М., 2002.
4. Ланкин В.З., Тихазе А.К., Беленков Ю.Н. Антиоксиданты в комплексной терапии атеросклероза: pro et contra. Кардиология. 2004; 2: 72–81.
5. Леонтьева И.В. Нарушения клеточной энергетики при кардиомиопатиях и возможности применения коэнзима Q10 в лечении. Cons. Med. Педиатрия (Прил.). 2007; 5.
6. Школьникова М.А. Отчет Ассоциации детских кардиологов России по применению Кудесана. Применение антиоксидантного препарата кудесан (коэнзим Q10 с витамином Е) в кардиологии. М., 2002.
7. Baggio E, Gandini R et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994; 15: 287–94.
8. Beal MF. Coenzyme Q administration and its potential for treatment of neurodegenerative diseases. Biofactors 1999; 9: 261–6.
9. Belardinelli R, Mucaj A, Lacalaprice F at al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J 2006; 27: 2675–81.
10. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. South Med J 2001; 91 (11): 1112–7.
11. Crane F, Sun IL, Sun EE. The essential function of coenzyme Q10. Clin Invest 1993; 71: 55–9.
12. Crane FL, Hatefi Y, Lester RL, Widmer G. Isolation of a quinone from beef heart mitochondria. Biochem Biophys Acta 1957; 25: 220–1.
13. Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006; 47: 1–7.
14. Filipek PA, Juranek J, Smith M et al. Mitochondrial disfunction in autistic patients with 15q inverted duplication. Ann Neurol 2003; 53: 801–4.
15. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA 1985; 82: 901–4.
16. Hemmi N, Bhagavan, Raj K Chopra. Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy. Clin Nutrition 2005; 24: 331–8.
17. Hershey AD, Powers SW, Vockell AB et al. Coenzyme Q10 Deficiency and Response to Supplementation in Pediatric and Adolescent Migraine. Headache 2007; 47 (1): 73–80.
18. Judy WV, Stogsdill WW, Folkers K. Myocardial preservation by therapy with coenzyme Q10 during heart surgery. Clin Investig 1993; 71 (8): 155–61.
19. Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 1997; 18: 145–51.
20. Larussi A et al. Protective effect of coenzyme Q10 on anthracycline cadiotoxicity: Control study in children with acute lymphoblastic leukemia and non-hodgkin lymphoma. Molec Aspects Med 1994; 15: s207–s212.
21. Linnane AW, Eastwood H. COENZYME Q10 – Antioxidant, Redox Mitochondrion. 2004; 1 (11).
22. Marin-Garcia J, Ananthakrishnan R, Michael J. Goldenthal, Mitochondrial Dysfunction in Skeletal Muscle of Children With Cardiomyopathy. Pediatrics 1999; 103 (2):  456–9.
23. Menke T, Niklowitz P, Adam S et al. Simultaneous detection of ubiquinol-10, ubiquinone-10 and tocopherols in human plasma microsamples and macrosamples as a marker of oxidative damage in neonates and infants. Anal Biochem 2000; 282: 209–17.
24. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig 1993; 71 (Suppl. 8): S116–23.
25. Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of «Q-symbio» – a multinational trial. Biofactors 2003; 18: 79–89.
26. Oda T. Recovery of the Frank–Starling mechanism by coenzyme Q10 in patients with load-induced contractility depression. Mol Aspects Med 1994; 15 (Suppl.): 149–54.
27. Passi S, de Pita O, Puddu P, Littarru GP. Protective effect of coenzyme Q10 on anthracycline cadiotoxicity: Control study in children with acute lymphoblastic leukemia and non-hodgkin lymphoma. Lipophilic Antioxidants in Human Serum and Aging. Free Radic Res 2002; 36 (4): 471–7.
28. Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect ofcoenzyme Q10 in phtysical exercise, hypertension and heart failure. Biofactors 2003; 18 (1–4): 91–100.
29. Rosenfeldt FL, Pepe S, Linnane A et al. Coenzyme Q10 protect the aging heart against stress: studies in rats, human tissues, and patients. Ann NY Acad Sci 2002; 959: 355–9.
30. Rotig A, Appelkvist EL, Geromel V et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000; 356: 391–5.
31. Sándor PS, Di Clemente L, Coppola G et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005; 64: 713–5.
32. Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinsons disease. Biofactors 1999; 9: 267–72.
33. Singh RB, Neki NS et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cll Biochem 2003; 264 (1–2): 75–82.
34. Singh RB, Niaz MA, Rastogi SS et al. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients withcoronary artery disease. J Hum Hypertens 1999; 13 (3): 203–8.
35. Singh RB, Niaz MA. Serum concentration of lipoprotein (a) decreases on treatment with hydrsoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role. Int J Cardiol 1999; 68 (1): 23–9.
36. Singh RB, Shinde SN, Chopra RK et al. Effect of coenzyme Q10 on experimental atherosclerosis and chemical composition and quality of atheroma in rabbits. Atherosclerosis 2000; 148 (2): 275–82.
37. Suzuki T, Koizumi J, Shiraishi H et al. Mitochondrial encephalomyopathy (MELAS) with mental disorder. CT, MRI and SPECT findings. Neuroradiology 1990; 32 (1): 74–6.
38. Захарова И.Н., Обыночная Е.Г., Скоробогатова Е.В., Малашина О.А. Влияние антиоксиданта на основе убихинона – кудесана на активность перекисного окисления липидов и антиоксидантную защиту у детей. Педиатрия. 2005; 4: 75–8.
39. Творогова Т.М., Захарова И.Н., Коровина Н.А. и др. Терапия Коэнзимом Q10 (Кудесаном): фокус на кардиальные изменения при вегетативной дистонии у детей и подростков. Педиатрия. 2009; 2: 86–91.
40. Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol Aspects Med 1994; 15: 143–7.
41. Аронов Д.М., Иоселиани Д.Г., Красницкий В.Б. и соавт. Рандомизированное проспективное исследование лекарственного препарата Кудевита (коэнзима Q10) в лечении пациентов с ишемической болезнью сердца с сердечной недостаточностью II–III функционального класса. Cons. Med.  2012; 14 (1): 55–60.

С.О.Ключников

Кафедра госпитальной педиатрии №1 ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва